Evidence map›Paper›PMID 30227415›Full record

ArticleOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde2019

Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography.

Jan H de Jong, Boy Braaf, Sankha Amarakoon, Maximilian Gräfe, Suzanne Yzer, Koenraad A Vermeer, Tom Missotten, Johannes F de Boer, Mirjam E J van Velthoven

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. [Diagnostic criteria: OCT angiography for retinal angiomatous proliferation (RAP lesions, type 3 neovascularization)].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jan H de JongRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Boy BraafInstitute for Lasers, Life and Biophotonics Amsterdam, Department of Physics and Astronomy, VU University, Amsterdam, The Netherlands.
Sankha AmarakoonRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Maximilian GräfeInstitute for Lasers, Life and Biophotonics Amsterdam, Department of Physics and Astronomy, VU University, Amsterdam, The Netherlands.
Suzanne YzerRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Koenraad A VermeerRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Tom MissottenRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Johannes F de BoerRotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Mirjam E J van VelthovenRotterdam Ophthalmic Institute, Rotterdam, The Netherlands, M.vanVelthoven@oogziekenhuis.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis prospective case series is aimed at exploring optical coherence tomographic angiography (OCT-A) as a treatment monitoring tool in patients treated for retinal angiomatous proliferation (RAP).

methodsTwelve treatment-naïve RAP patients were included, with a median age of 79 years (range 65-90). Patients were imaged with an experimental 1,040-nm swept-source phase-resolved OCT-A instrument before and after treatment. Treatment consisted of either intravitreal bevacizumab or triamcinolone injections with or without photodynamic therapy (PDT). Abnormal blood flow after treatment was graded as increased, unchanged, decreased, or resolved.

resultsOCT-A images before and after treatment could be obtained in 9 patients. The median follow-up period was 10 weeks (range 5-19). After various treatments, the RAP lesion resolved in 7 patients, in 1 patient the OCT-A depicted decreased flow in the lesion, and 1 patient showed unchanged abnormal blood flow. Monotherapy with intravitreal bevacizumab injections resolved RAP in 1 out of 2 patients. Combined therapy of bevacizumab with PDT resolved RAP in 6 out of 7 patients.

conclusionsOCT-A visualized resolution of abnormal blood flow in 7 out of 9 RAP patients after various short-term treatment sequences. OCT-A may become an important noninvasive monitoring tool for optimizing treatment strategies in RAP patients.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsBevacizumabDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiGlucocorticoidsHumansIntravitreal InjectionsMacular DegenerationMalePhotochemotherapyAngiogenesis InhibitorsBevacizumabGlucocorticoidsPhotosensitizing AgentsReceptors, Vascular Endothelial Growth FactorTriamcinoloneAnti-VEGF therapyImagingOptical coherence tomographic angiographyPhotodynamic therapyRetinal angiomatous proliferationTreatment monitoringType 3 neovascularization

Identifiers

PMID30227415
PMCPMC6492610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.